NervGen's NVG-291 Shows Genuine Neural Recovery in Spinal Cord Injury Study

Event summary

  • NervGen's NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197) in Phase 1b/2a CONNECT SCI study.
  • 100% of NVG-291 subjects classified as responders versus 10% of placebo subjects (p=0.0001).
  • Biomechanical gait analyses conducted by Newton Tech and verified by Department of Computational Biomedicine.
  • NervGen plans to initiate Phase 3 RESTORE registrational study in mid-2026.

The big picture

NervGen's positive biomechanical gait analyses for NVG-291 represent a significant milestone in the treatment of chronic spinal cord injury. The results suggest genuine neural recovery, addressing a critical unmet need in the neurology sector. With FDA alignment and plans for a Phase 3 study, NervGen is positioning NVG-291 as a potential first-in-class pharmacologic therapy, which could transform the treatment paradigm for neurotraumatic conditions.

What we're watching

Regulatory Pathway
Whether the FDA's alignment on the Phase 3 RESTORE study will expedite approval for NVG-291.
Clinical Execution
The pace at which NervGen can activate clinical sites and initiate the Phase 3 study.
Market Differentiation
How NVG-291's demonstrated neural recovery will position it as a best-in-class therapy for chronic tetraplegia.